Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,365,520
  • Shares Outstanding, K 110,018
  • Annual Sales, $ 7,863 M
  • Annual Income, $ 2,116 M
  • 60-Month Beta 0.52
  • Price/Sales 7.02
  • Price/Cash Flow 20.71
  • Price/Book 4.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 5.91
  • Number of Estimates 1
  • High Estimate 5.91
  • Low Estimate 5.91
  • Prior Year 3.75
  • Growth Rate Est. (year over year) +57.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
418.01 +22.71%
on 03/13/20
518.00 -0.97%
on 03/19/20
+38.52 (+8.12%)
since 03/09/20
3-Month
328.13 +56.33%
on 01/31/20
518.00 -0.97%
on 03/19/20
+129.49 (+33.77%)
since 01/09/20
52-Week
271.37 +89.03%
on 09/27/19
518.00 -0.97%
on 03/19/20
+117.23 (+29.62%)
since 04/09/19

Most Recent Stories

More News
Coronavirus Testing, Vaccines & Treatments: What You Should Know

We discuss latest developments in tests, vaccines and therapies for COVID-19.

JNJ : 141.23 (-1.42%)
REGN : 512.96 (+0.12%)
GILD : 73.51 (-1.97%)
MRNA : 31.86 (-1.73%)
ABT : 86.04 (+1.28%)
VHT : 177.74 (+0.91%)
XBI : 83.43 (+1.88%)
Alnylam (ALNY) Completes Rolling Submission of Lumasiran NDA

Alnylam (ALNY) completes rolling submission of the NDA for lumasiran seeking approval for kidney disease, primary hyperoxaluria type 1. The EMA accepts MAA for lumasiran for the same indication.

REGN : 512.96 (+0.12%)
SNY : 45.46 (+0.62%)
ALNY : 116.38 (+4.48%)
NVS : 84.85 (-0.90%)
4 Stocks Trading Near 52-Week High That Can Scale Higher

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

REGN : 512.96 (+0.12%)
ABC : 87.81 (-0.59%)
ELMD : 12.25 (+0.82%)
EBS : 62.64 (+1.15%)
Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)

Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau

REGN : 512.96 (+0.12%)
ZLAB : 59.92 (+8.73%)
Regeneron (REGN) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Regeneron (REGN) closed at $501.51, marking a -0.55% move from the previous day.

REGN : 512.96 (+0.12%)
Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

JNJ : 141.23 (-1.42%)
REGN : 512.96 (+0.12%)
SNY : 45.46 (+0.62%)
RHHBY : 39.7500 (-1.49%)
DVAX : 2.94 (-6.67%)
PFE : 35.39 (+2.28%)
GILD : 73.51 (-1.97%)
INCY : 86.81 (-1.07%)
MRNA : 31.86 (-1.73%)
GSK : 38.88 (+2.10%)
NVS : 84.85 (-0.90%)
AMGN : 218.21 (-0.45%)
NVAX : 17.05 (-0.76%)
TBI : 14.42 (+1.98%)
Esperion's Cholesterol Drugs Receive Approval in Europe

Esperion (ESPR) announces approval for cholesterol drugs Nilemdo and Nustendi in Europe.

REGN : 512.96 (+0.12%)
SNY : 45.46 (+0.62%)
MRK : 82.49 (+1.07%)
ESPR : 35.56 (-1.19%)
Gilead Partners Second Genome, Boosts Coronavirus Drug Production

Gilead (GILD) collaborates with Second Genome for inflammatory bowel disease treatments. The company also plans to ramp up production of remdesivir for coronavirus treatment.

JNJ : 141.23 (-1.42%)
REGN : 512.96 (+0.12%)
SNY : 45.46 (+0.62%)
GILD : 73.51 (-1.97%)
The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale

The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale

REGN : 512.96 (+0.12%)
MRNA : 31.86 (-1.73%)
COST : 300.01 (-1.95%)
ZM : 124.51 (+5.69%)
PTON : 28.45 (+3.45%)
Is Pharma the Sector to Bet on in 2020? 2 Big Stocks to Buy

Here we have highlighted two big pharma stocks that may prove to be good buys. Both these stocks carry a Zacks Rank #1 (Strong Buy) and have seen their share price rise this year.

JNJ : 141.23 (-1.42%)
REGN : 512.96 (+0.12%)
SNY : 45.46 (+0.62%)
GILD : 73.51 (-1.97%)
MRNA : 31.86 (-1.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 524.59
1st Resistance Point 518.78
Last Price 512.96
1st Support Level 504.01
2nd Support Level 495.05

See More

52-Week High 518.00
Last Price 512.96
Fibonacci 61.8% 423.79
Fibonacci 50% 394.68
Fibonacci 38.2% 365.58
52-Week Low 271.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar